Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
The new manufacturer’s data provide another route for FDA review while the original vendor’s reinspection remains pending.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Unicycive Therapeutics (UNCY) resubmitted its FDA new drug application for oxylanthanum carbonate to treat high phosphate levels in dialysis patients.
The application includes manufacturing data from a new drug-product vendor, 12 months of product stability data and laboratory comparisons between the two vendors. The new vendor’s facility received a “No Action Indicated” FDA inspection classification in March 2024. Unicycive expects the FDA to accept the application within 30 days and assign a review deadline six months after resubmission.
The FDA’s June 2026 response letter cited previously identified manufacturing deficiencies at the original vendor. The FDA raised no concerns about clinical efficacy or safety data and requested no additional company data. The original vendor’s reinspection had not occurred as of September 29, 2026. Unaudited cash, cash equivalents and marketable securities totaled $61.4 million at June 30, supporting an expected cash runway into the second half of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointOLC application resubmitted for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis.
- Moderate pointFDA review raised no concerns about clinical efficacy or safety data and requested no additional company data.
- Moderate point. Forward-looking: it has not happened yet and may not happen.FDA acceptance is expected within 30 days, with a new review deadline expected six months after resubmission.
- Moderate point. Forward-looking: it has not happened yet and may not happen.$61.4 million in unaudited cash, cash equivalents and marketable securities at June 30 supports an expected runway into the second half of 2027.
- Minor pointNew vendor’s manufacturing package includes 12 months of OLC drug-product stability data.
2 minor points
- Minor pointNew vendor’s facility received a “No Action Indicated” FDA inspection classification in March 2024.
- Minor point. Forward-looking: it has not happened yet and may not happen.Two drug-product vendors are planned to maintain supply-chain redundancy.
Negative
- Major pointJune 2026 FDA response letter cited manufacturing deficiencies at the original vendor previously identified in June 2025.
- Moderate pointOriginal vendor’s reinspection had not occurred as of September 29, 2026, despite being assigned.
- Minor pointFDA approval of investigational OLC remains pending.
News Explained
A shorter review is not assured: even a favorable inspection would lead only to a request for FDA alignment.
For the OLC resubmission, Unicycive says it intends to keep both drug-product vendors, making the new vendor an additional source rather than a replacement for the original.
The original vendor’s FDA inspection has been assigned but has not occurred; if it happens soon and finds the facility compliant, the company plans to seek FDA alignment on a shorter approval timeline.
Details
Market move: UNCY +12.07% vs previous close. NDA resubmission
On Sep 29, the day this news came out, the latest delayed price for UNCY is 12.07% above the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $5.20. Relative volume is exceptionally heavy at 32.0x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Anticipated FDA acceptance
- within 30 days
- After NDA resubmission
- Expected PDUFA timing
- 6 months
- From resubmission
- Drug product stability data
- 12 months
- OLC product from the new manufacturing vendor
- New vendor facility inspection
- March 2024
- FDA inspection; received “No Action Indicated” status
- Cash, cash equivalents and marketable securities
- $61.4 million
- Unaudited, as of June 30, 2026
- Expected cash runway
- into the second half of 2027
- Company estimate
Previous Clinical trial Reports
-
CRL cited third-party manufacturing deficiencies; FDA raised no efficacy or safety concerns.
-
FDA accepted OLC NDA resubmission and assigned a June 27, 2026 PDUFA target.
-
Company resubmitted OLC NDA, citing expected 30-day acceptance and six-month review.
-
After June CRL, company outlined planned resubmission following a vendor-compliance deficiency.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
new drug application (nda) regulatory
chemistry, manufacturing, and controls (cmc) regulatory
pdufa regulatory
complete response letter (crl) regulatory
cgmp regulatory
505(b)(2) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Resubmission of NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor
- The resubmission package includes 12 months of OLC drug product stability data from the new manufacturing vendor
- Company anticipates FDA acceptance of the NDA within 30 days of resubmission; new assigned PDUFA date expected to be 6 months from resubmission
- Current cash position allows runway into 2H 2027
MOUNTAIN VIEW, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The Company anticipates United States Food and Drug Administration (FDA) acceptance of the NDA within 30 days and a new assigned PDUFA date to be six months from the date of resubmission.
The NDA resubmission includes CMC data from a new third-party drug product manufacturing vendor. The new vendor’s facility was last inspected by the FDA in March 2024 and received “No Action Indicated” status, the highest FDA inspection classification indicating that a facility is in an acceptable state of current Good Manufacturing Practices (cGMP) compliance. The new vendor's CMC data package includes technical specifications similar to the original third-party manufacturing vendor, and the new vendor has already produced OLC drug product and completed 12-month stability studies. In addition, the Company has provided additional in-vitro bridging data between the two vendors as recommended by the FDA in previous discussions.
In June 2026, the Company received a Complete Response Letter (CRL) from the FDA regarding the first OLC NDA resubmission. The 2026 CRL cited the same third-party manufacturing deficiencies identified in a previous CRL issued in June 2025 to the initial NDA submission, as a result of the FDA not having conducted the reinspection of the original third-party manufacturing vendor. The FDA did not raise concerns regarding clinical efficacy or safety data and did not request additional data from the Company. The Company’s original third-party manufacturing vendor has received written notification from the FDA that its facility inspection has been assigned, but the inspection has not yet occurred as of September 29, 2026. If the original third-party manufacturing vendor is inspected in the near term and deemed cGMP-compliant, the Company plans to seek FDA alignment on a shorter approval timeline for the OLC NDA resubmission. Unicycive intends to keep both drug product vendors to maintain supply chain redundancy.
“We believe this resubmission reflects an efficient path to potential approval and, if approved, a potentially faster path to bringing OLC to patients who need additional treatment options,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “By adding an alternative primary manufacturing vendor, we are positioning the NDA for expedient review and potential approval. If the FDA’s assigned inspection of the original vendor is completed favorably in the interim, that outcome could provide a potential timing benefit. We continue to advance commercial readiness activities in anticipation of a potential launch, with the goal of helping patients with CKD on dialysis who continue to struggle with hyperphosphatemia.”
The NDA is supported by data from three clinical studies: a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis, along with multiple preclinical studies and CMC data.
As of June 30, 2026, unaudited cash, cash equivalents and marketable securities totaled
About Oxylanthanum Carbonate
OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.
About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.
1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of our NDA; the risk that the original third-party manufacturing vendor’s reinspection may not occur within a timeframe that benefits our regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Unicycive Therapeutics
media@unicycive.com
SOURCE: Unicycive Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.